4.1 Article

Neurodegenerative Disease Phenotypes in Carriers of MAPT p.A152T, A Risk Factor for Frontotemporal Dementia Spectrum Disorders and Alzheimer Disease

期刊

ALZHEIMER DISEASE & ASSOCIATED DISORDERS
卷 27, 期 4, 页码 302-309

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WAD.0b013e31828cc357

关键词

all cognitive disorders; dementia; Alzheimer disease; frontotemporal dementia; corticobasal degeneration; progressive supranuclear palsy

资金

  1. Tau Consortium
  2. FRSQ [R01AG034499-02, R01 AG026938]
  3. Scientific and Technological Research Council of Turkey [104S255]
  4. NIH [R01 NS065782, R01AG02651, P50 AG16574, P50 AG1657303]
  5. ALS association, CurePSP
  6. Consortium for Frontotemporal Dementia Research
  7. Alzheimer's Drug Discovery Foundation, CurePSP, the Hellman Family Foundation [2R01AG022983, R01AG038791, R01AG031278]
  8. Michael J. Homer Family Fund
  9. John Douglas French Alzheimer's Foundation [K23-AG031861]
  10. Alzheimer's Research Center of California [AG19724, AG023501, 01-154-20, UL1 RR024131-06]
  11. John Douglas French Alzheimer's Disease Foundation
  12. James S. McDonnell Foundation
  13. Larry Hillblom Foundation
  14. Medical Advisory Board of the Association for Frontotemporal Dementia
  15. Allon Therapeutics
  16. Avid
  17. Elan
  18. Forest
  19. Genentech
  20. Janssen
  21. Medivation
  22. Pfizer
  23. Avid Radiopharmaceuticals
  24. Novartis
  25. [K23AG039414-01A1]
  26. [5R01AG031189-2]
  27. [R01NS050915]

向作者/读者索取更多资源

Recently, Coppola and colleagues demonstrated that a rare microtubule-associated protein tau (MAPT) sequence variant, c.454G>A (p.A152T) significantly increases the risk of frontotemporal dementia (FTD) spectrum disorders and Alzheimer disease (AD) in a screen of 15,369 subjects. We describe clinical features of 9 patients with neurodegenerative disease (4 women) harboring p.A152T, aged 51 to 79 years at symptom onset. Seven developed FTD spectrum clinical syndromes, including progressive supranuclear palsy syndrome (n=2), behavioral variant FTD (bvFTD, n=1), nonfluent variant primary progressive aphasia (nfvPPA, n=2), and corticobasal syndrome (n=2); 2 patients were diagnosed with clinical AD. Thus, MAPT p.A152T is associated with a variety of FTD spectrum clinical presentations, although patients with clinical AD are also identified. These data warrant larger studies with clinicopathologic correlation to elucidate the influence of this genetic variant on neurodegenerative disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据